{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-037724","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.896095+00:00","generated_at":"2026-05-15T08:07:43.442310+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tvardi reports 2025 net loss $18.2M; cash to fund into Q4 2026; key clinical milestones ahead","bullets":["Net loss for 2025 was $18.2M ($2.46 basic EPS); cash $30.8M expected to fund operations into Q4 2026.","R&D expenses decreased to $18.0M in 2025 from $23.7M in 2024, driven by lower TTI-101 clinical costs.","Phase 2 IPF trial of TTI-101 showed 9.4% fibrosis reduction vs 2.4% placebo; IL-6 declined 4.5-fold.","Topline data from TTI-109 healthy volunteer study expected Q2 2026; TTI-101 HCC Phase 2 data in H2 2026.","G&A expenses rose to $8.7M in 2025 from $4.5M in 2024 due to merger-related professional fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-037724","json":"https://secwatch.observer/filing/0001104659-26-037724.json","markdown":"https://secwatch.observer/filing/0001104659-26-037724.md","text":"https://secwatch.observer/filing/0001104659-26-037724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926037724/0001104659-26-037724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926037724/tm2610603d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:07:43.442310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1fd7f9ec9dbcbd8ccef592af16db532d0d6845df","claim":"Tvardi Therapeutics, Inc. reported the fourth quarter and full-year ended December 31, 2025 results: net income Net loss for the three months ended December 31, 2025, was $7.3 million...For the full year 2025, net loss was $18.2 mil, EPS Basic and diluted net loss per share...for the three months ended December 31, 2025, were a net loss of $(0.78) on a bas.","evidence_excerpt":"On March 31, 2026, Tvardi Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the fiscal quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926037724/0001104659-26-037724-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full-year ended December 31, 2025"},{"label":"Net income","value":"Net loss for the three months ended December 31, 2025, was $7.3 million...For the full year 2025, net loss was $18.2 mil"},{"label":"EPS","value":"Basic and diluted net loss per share...for the three months ended December 31, 2025, were a net loss of $(0.78) on a bas"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}